Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo-Reference-Cited by-同舟云学术

Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo

Published:2006-06-10 Issue:14 Volume:49 Page:4356-4366
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Shami Paul J.¹,Saavedra Joseph E.¹,Bonifant Challice L.¹,Chu Jingxi¹,Udupi Vidya¹,Malaviya Swati¹,Carr Brian I.¹,Kar Siddhartha¹,Wang Meifeng¹,Jia Lee¹,Ji Xinhua¹,Keefer Larry K.¹

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah 84112, Basic Research Program, SAIC Frederick, Chemistry Section, Laboratory of Comparative Carcinogenesis, and Macromolecular Crystallography Laboratory, National Cancer Institute at Frederick, Frederick, Maryland 21702, Liver Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, and Developmental Therapeutics Program, National Cancer Institute, Rockville, Maryland 20852

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm060022h

Reference33 articles.

1. Influence of First-Line Regimens on the Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma.

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Cytotoxic Nitric Oxide-Releasing Piperlongumine Derivatives Targeting Wnt/β-Catenin in Colon Cancer Cells;Journal of Natural Products;2024-07-24

2. Novel Nitric Oxide Donor–Azole Conjugation Strategy for Efficient Treatment of Cryptococcus neoformans Infections;Journal of Medicinal Chemistry;2023-10-11

3. NO donors as the wonder molecules with therapeutic potential: Recent trends and future perspectives;Coordination Chemistry Reviews;2023-04

4. Development of JS-K, a First-in-Class Arylated Diazeniumdiolate, for the Treatment of Cancer;Critical Reviews™ in Oncogenesis;2023

5. Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer;Critical Reviews™ in Oncogenesis;2023